A procedure for efficient transfer of the human MDR7 (multidrug resistance) gene into murine hematopoietic stem cells was developed. Cells expressing Sca-l but no lineage-specific or major histocompatibility complex (MHC) class II antigens (Lin-MHC Il-Sca-l+) were enriched from 5-fluorouracilpretreated bone marrow by Ficoll density-gradient and i r nmunomagnetic sorting. Purified cells were cocultured with growth factors and fibroblasts producing replication-deficient retroviruses containing human MDR7 cDNA. Fluorescence-activated cell sorter analysis and rhodamine-l23 efflux experiments showed that greater than 60% of cocultured hematopoietic cells expressed functional human P-glycoprotein. After 6 t o 8 days, hematopoietic cells were injected intravenously into sublethally irradiated SClD mice. Stem cell properties of the isolated population were confirmed by sustained expression of MDR7 marker cDNA for G
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ENE THERAPY for hematopoietic disorders requires highly efficient transfer of the respective gene into the target cell population to ensure sufficient expression of the encoded protein. Hematopoietic stem cells, a rare population in bone marrow, are optimal targets for gene therapy because these cells have the ability to differentiate into all lineages of hematopoietic cells and have a virtually infinite life span because of unlimited self-renewal. Thus, genes transferred into stem cells may be stably expressed long term in hematopoietic tissues, whereas targeting of more mature progenitor cells may result only in transient gene expression. Although incidental targeting of stem cells by gene transfer into whole bone marrow has been confirmed in numerous investigations, efficient retroviral gene transduction into isolated stem cells has been found to be more difficult.' Thus, in several gene transfer protocols, hematopoietic cells are first exposed to retroviruses that contain drug resistance genes, followed by a selection step in vitro to eliminate nontransduced cells.
The majority of hematopoietic stem cells remain in a quiescent state in vivo, whereas retroviral gene transfer requires cell proliferation.' Activation of stem cells is accomplished in vivo by treatment with 5-fluorouracil* and in vitro by the use of hematopoietic growth factors and cytokines.' Several studies have established the benefit of combinations of these factors because they act synergistically on stem cells and increase the efficiency of gene transduction into hematopoietic cells. Although growth of hematopoietic stem cells is frequently accompanied by differentiation resulting in loss of the stem cell phenotype, a stem cell phenotype can be preserved at least in a proportion of cells under suitable conditions in culture. Recent reports have shown the feasibility of integrating foreign genes into isolated hematopoietic progenitor or stem Although different protocols have been used to isolate cell populations with pluripotent stem cell characteristics, it is well established that murine stem cells are immunologically characterized by the absence of lineage-specific differentiation markers and expression of certain antigens such as Sca-1 (Ly6-AIE), the c-kit protein, and low levels of Thyl .2. [7] [8] [9] Comparable studies on human hematopoiesis showed Blood, Vol 86, No 1 (July l), 1995: pp 111-121 greater than 4 t o 6 months after transplantation, multilineage engraftment, and presence of MDR7 cDNA in bone marrow of secondary recipient mice after retransplantation. Reconstitution of H-2K-mismatched SClD mice showed high engraftment capacity of Lin-MHC Il-Sca-l+ cells. MDR7 cDNA was detected in blood of 78% of recipients. P-glycoprotein was expressed in bone marrow of 71% of mice, in both lymphocytes and myelomonocytoid progenitors. P-glycoprotein function in host marrow was confirmed by rhodamine-l23 efflux. Transduction of P-glycoprotein may be useful for gene therapy in two ways: t o protect bone marrow from myelosuppression after chemotherapy and as a selectable marker in vivo for the introduction of otherwise nonselectable genes. This is a US government work. There are no restrictions on its use.
that a subset of cells that do not express the major histocompatibility complex (MHC) class I1 antigen, HLA-DR, is believed to consist of primitive, pluripotent stem cells with high capacity of differentiation into all lineages of mature cells, whereas other subsets of stem cells are more restricted to certain
Based on these findings, in this study we purified in this study mouse cells that expressed Sca-l but no lineage or I-a (MHC class 11) antigens (Lin-MHC II-Sca-l+ cells). Immunomagnetic particles were used for sorting of these cells because this method is rapid and produces enriched cells of high viability. We show here that the purified cells have characteristics of hematopoietic stem cells.
Transfer of the MDRl gene, which encodes P-glycoprotein, into hematopoietic stem cells is of particular interest for gene therapy not only because it may protect hematopoietic cells from the toxicity of antineoplastic drugs, but also because it has been found to act as a selectable marker in gene, is a transmembrane protein that extrudes a broad variety of natural cytotoxins including colchicine and drugs used for antineoplastic chemotherapy, eg, Vinca alkaloids, anthracyclines, and taxol." Because of its wide substrate specific-The aim of our study was to develop conditions for efficient expression of a functional human MDRl gene in vivo after transfer into purified progenitor cells with stem cell properties. Murine hematopoietic progenitor cells were isolated with immunomagnetic particles first by depleting cells expressing lineage-specific and I-a (MHC class 11) antigens and second by positive sorting for Sca-l expression. We describe here a coculture system for retroviral transduction into Lin-MHC II-Sca-l+ cells by which expression of the encoded protein i s achieved in the majority of cells. We find expression of functional P-glycoprotein at levels comparable to colchicine-selected KB-8-5 multidrug-resistant tumor cells" in the bone marrow of recipient SCID mice after transplantation of the transduced cells.
MATERIALS AND METHODS
Mice. C57BL/6 were obtained from the National Cancer Institute Frederick Cancer Research and Development Center (Frederick, MD). CB.17-SCID mice were from Charles River Laboratories (Wilmington, MA). C57BU6-SCID-SzJ mice were from Jackson Laboratories (Bar Harbor, ME). SCID mice were kept in microisolator cages and provided with sterile food and water. The genetic background of C57BL/6 and C57BL/6-SCID-SzJ mice is identical except for the SCID mutation. Both strains express the H-2Kb antigen, whereas CB.17-SCID mice display the H-2Kd phenotype.
Sorting of murine hematopoietic stem cells. Six to twelve-weekold male C57BW6 mice were treated intravenously (IV) with IS0 mgkg 5-fluorouracil (Sigma, St Louis, MO) 2 to 6 days before harvest of bone marrow. The bone marrow of 10 to 20 animals was harvested from both femurs and tibias, and low-density mononuclear cells were isolated by Ficoll density-gradient centrifugation (Pharmacia, Piscataway, NJ). After two washings with Iscove's medium (Iscove's modified Dulbecco's medium [IMDM] ; GIBCO, Gaithersburg, MD), hematopoietic progenitor cells were enriched as follows. Cells were incubated for 20 minutes at 4°C with sheep-antirat-Igcoated Dynabeads (Dynal, Grand Neck, NY) that had been preincubated with a cocktail of monoclonal rat antibodies to I-ab at 10 pg (MHC class 11) and lineage antigens (Lin). Lineage markers included monoclonal antibodies (MoAbs) Gr-l (10 pg), towards a myeloid differentiation antigen; MAC-l (20 pg) against myelomonocytoid cells; TER119 (IO pg) against erythroid cells; B220 at 10 pg (CD45R), which reacts mainly with B and pre-B cells; and antibodies to T-cell antigens, CD8a ( 5 pg) and CD3 (IO pg). We modified a previously described protocol' for characterization of lineage-committed cells by use of an antibody to a pan-T-cell antigen, CD3, instead of CD4, which may be expressed on stem cells?' All antibodies were purchased from Pharmingen (San Diego, CA) except CD3 (GIBCO). Cells expressing these antigens were depleted twice using an MPC-I magnet (Dynal). Remaining cells were washed with 10 mL of medium and then incubated with Dynabeads that were labeled with MoAb Sca-l (Pharmingen). After 20 minutes cells bound t o the beads were magnetically isolated and again washed with medium. This magnetic isolation step was repeated twice.
Analysis of enrichment by this procedure was performed by sorting with Dynabeads and antibodies labeled with fluorescent compounds. Sca-l was conjugated to fluorescein isothiocyanate (FITC) and the other antibodies were conjugated to phycoerythrin (PE).
Thereby we were able to analyze the sorted population directly without restaining the cells. The enriched population was compared with whole normal bone marrow stained with the respective fluorescent antibodies bound to Dynabeads. Isotype-identical nonbinding antibodies (Pharmingen) were coupled to Dynabeads and used as negative controls for the analysis of unseparated cells. No significant differences were observed when bone marrow cells were either stained with fluorescent MoAbs or when fluorescent antibodies were bound to beads. Fluorescence-activated cell sorter (FACS) analyses were performed using a FACSort cytometer with LYSIS I1 software (Becton Dickinson, San Jose, CA). A gate was drawn by forwardand side-scatter properties that excluded 99.96% of beads. To analyze the Lin-MHC 11-Sca-l' subpopulation after coculturing for 6 days, cells were resorted using a MiniMACS separation kit (Miltenyi, Sunnyvale, CA). Cells were first labeled for 15 minutes at 4°C with the described mixture of antibo&es to lineage and MHC class I1 antigens in phosphate-buffered saline (PBS) containing 0.5% bovine serum albumin (BSA) and 5 mmol/L EDTA. After washing in the same buffer, they were incubated with 20 pL goat-antiratIgG microbeads (Miltenyi) for 12 minutes at 4°C. Cells labeled with microbeads were depleted using separation columns according to the manufacturer's instructions. In a second step cells were stained with I O pg MoAb Sca-l for 15 minutes. After washing with buffer, they were labeled with 20 pL goat-antirat-IgG microbeads for 12 minutes at 4°C. After an additional washing, cells were isolated with a separation column. The resorted Lin-MHC 11-Sca-l+ cells were then analyzed for rhodamine-l23 efflux or reactivity with MoAb MRK16 as described below.
Gene tmnsduction in coculture. The vector pHaMDRl/A containing a full-length MDRl cDNA under control of a Harvey sarcoma virus long terminal repeat was constructed in this laboratory." An ecotropic replication-deficient pHaMDRI/A retrovirus producer line GP + E86 MDRIIA" was generously provided by A. Bank (Columbia University, New York, NY). Virus titers of more than 5 X IO5 colony-forming units (CFU)/mL were obtained by subcloning GP + E86 MDRI/A cells and growing them in the presence of colchicine at 60 ng/mL. GP + E86 + N2 cells (also provided by A. Bank) producing virus particles that contain a neomycin-resistance (neoR) gene were used as a negative control for the transduction of the MDRl cDNA.
Purified bone marrow cells were transferred to 75 cm' tissue culture flasks with adherent virus producers pregrown to 30% to 40% confluence. They were cocultured in IMDM with 20% fetal bovine serum (FBS; Hyclone, Logan, UT) supplemented with 50 U/ mL penicillin, SO pg/mL streptomycin, 0.5 pmol/L 2-mercaptoethanol, and 4 pg/mL polybrene in the presence of a combination of recombinant growth factors: rat stem cell factor at 100 ng/mL (kindly provided by Amgen, Thousand Oaks, CA), murine interleukin-1P (IL-10) at 100 ng/mL (Peprotech, Rocky Hill, NJ), human recombinant erythropoietin at 1 U/mL (Sigma), murine IL-3 at 200 U h L , and human IL-6 at 200 U/mL (both from Becton Dickinson Labware, Bedford, MA). The hematopoietic cells expanded in coculture under these conditions. In a typical experiment their number increased MDR7 GENE TRANSFER INTO PURIFIED STEM CELLS 113 from 3 X IO4 to 2.8 X IO6 during a period of 8 days. A similar expansion of hematopoietic cells was observed in a control experiment using NIH 3T3 cells instead of GP + E86 MDRllA virus producers, but a lesser degree of expansion was observed in the absence of fibroblasts. Most of the immunomagnetic beads detached from the hematopoietic cells in coculture.
Transplantation of hematopoietic precursor cells. After 6 to 8 days nonadherent cells were harvested from cocultures. Cells still attached to Dynabeads were removed with a Biomag Separator magnet (Advanced Magnetics, Cambridge, MA). After three washings in PBS, indicated numbers of cells were injected in the lateral tail veins of sublethally irradiated (350 to 400 cGy) SCID mice. C57BL/ 6-SCID-SzJ were used for syngenic transplantation, whereas CB.17-SCID mice were reconstituted with MHC class l-mismatched progenitor cells. The latter approach allows the quantitation of donor versus host bone marrow cells. In one experiment, progenitor cells were transplanted into C57BW6-SCID-Szl mice without prior irradiation.
Two C57BL/6-SCID-Szl mice transplanted with 2.5 X 105 MDRItransduced cells shown to be positive for human MDRl DNA in peripheral blood were killed 9 weeks after transplantation and 1 X lo6 unseparated nucleated bone marrow cells were injected IV into sublethally irradiated secondary recipient CB.17-SCID mice.
Detection of MDRl cDNA by polymerase chain reaction (PCR). To prepare genomic DNA from blood or bone marrow, erythrocytes were first lysed with FACS lysing solution for IO minutes (Becton Dickinson). After two washings with PBS, white blood cells were lysed with ice-cold hypotonic buffer containing 0.5% NP40. Proteins were then digested with proteinase K for 1 hour at 5 6 T , followed by a denaturation step at 96°C for IO minutes. DNA from 70 pL of peripheral blood or 0.5 pg of DNA from bone marrow was used for PCR. Thirty-five cycles of PCR (92°C for 1 minutes, 52°C for 2 minutes, 72°C for 2 minutes) with primers specific for the human MDRI cDNA sequence, 5'-AGATCAACTCGTAGGAGTGTC-3' (forward) and 5'-GTITCTGTATGGTACCTGCAA-3' (reverse), amplifying a human MDRI fragment from nucleotide positions 1996 to 2790 were performed with a GeneAmp PCR kit (Perkin-Elmer Cetus, Norwalk, CT). Amplified DNA products were visualized by ethidium bromide staining on a 1.4% agarose gel.
Analysis of P-glycoprotein by FACS. MoAb MRK16 to P-glycoprotein,23 a gift of Hoechst Japan Ltd (Kawagoe City, Saitama, Japan), was conjugated to FITC in 0.5 m o m sodium carbonate buffer, pH 8.6, at room temperature for 1 hour. Unconjugated FlTC was removed by ultrafiltration with Centricon30 concentrators (Amicon, Beverley, MA).
The staining was performed as follows. Mononuclear bone marrow cells were prepared by Ficoll-separation. Floating cells from cocultures were harvested as described above. To reduce nonspecific binding, samples containing 2.5 X 10' cells were first incubated with 1 pg of a blocking Fc-receptor antibody (Pharmingen) in PBS containing 0.1% BSA. Five minutes later, 5 pg MRK16-FITC conjugate was added. After 20 minutes of incubation at 4"C, red blood cells were lysed with FACS lysing solution, and cells were washed twice with PBS. Each sample was compared with the respective cells stained with nonbinding murine IgG,-FITC conjugates at identical concentrations (Pharmingen or Becton Dickinson). In some experiments one control antibody (Pharmingen) showed fluorescence levels of nontransduced cells slightly above that obtained with MRK16. Thus, in some FACS analyses the number of cells expressing human P-glycoprotein may be underestimated.
Extrusion of rhodamine-123. To assess the transport function of P-glycoprotein, the efflux of rhodamine-123 was analyzed (Sigma). Mononuclear bone marrow cells or cells from cultures were incubated with rhodamine-l23 (1 pg/mL) in IMDM without phenol red containing 5% FBS for 15 minutes at 37°C and then centrifuged at 400g and resuspended in IMDM with 5% FBS in the presence or in the absence of verapamil at 20 to 25 pmol/L. After 120 minutes at 37"C, cells were pelleted and supernatants were removed. Tubes were transferred to ice, and cell fluorescence was immediately analyzed by FACS.
Analysis of donor-derived bone marrow subpopulations. H-2Kb-positive subpopulations of bone marrow cells from transplanted mice were isolated with a MiniMACS separator (Miltenyi) according to the manufacturer's instructions. In brief, mononuclear bone marrow cells were labeled on ice with biotinylated antibodies to the donortype MHC class I antigen, H-2Kb (Pharmingen). After incubation with streptavidin-conjugated microbeads (Miltenyi), cells were sorted using the magnetic device. Cells were washed twice in PBS containing 0.1% BSA. Then surface antigens were labeled with FITC-conjugated MoAbs (3-1, B220, and Thy-1.2 or with a nonbinding isotype control antibody. After two additional washings cells were analyzed by FACS.
RESULTS

Transduction of hematopoietic progenitor cells in coculture.
Murine bone marrow cells were sorted with immunomagnetic particles by tirst depleting lineage-committed cells and cells expressing the MHC class I1 antigen, I-ab. In a second step, cells that expressed the Sca-l antigen were isolated. The enrichment of Lin-MHC II-Sca-l+ cells was determined using antibodies labeled with fluorescent dyes (Fig 1) . The sorted population Lin-MHC 11-Sca-1' was enriched at least 210-fold as compared with normal bone marrow that contained 0.27% of these cells. In two separate experiments, the percentage of sorted Lin-MHC II-Sca-l+ cells was 56.5% and 68%. Cells expressing lineage or MHC class I1 antigens were almost completely removed by the procedure, being less than 0.5% of the purified population. The remaining cells expressed neither Sca-l nor lineage or MHC class I1 antigens.
Lin-MHC 11-Sca-l' cells were expanded in coculture with GP + E86 MDRl/A cells in the presence of a combination of growth factors including IL-lP, IL-3, IL-6, erythropoietin, and stem cell factor. After 6 days in vitro, 12% to 15% of cells maintained the primitive Lin-MHC 11-Sca-l' phenotype. At this time, subpopulations expressed myelomonocytoid differentiation antigens (MAC-l, 66%; Gr-l, 7.6%), whereas natural killer cells, T lymphocytes, or B lymphocytes were almost undetectable (all < 0.5%). Sca-l was still present on 53% of cells. Using MoAb MRK16, P-glycoprotein expression was tirst detected on nonadherent cells on day 4 of coculture with a further increase until day 6. This antibody is specitic for the product of the human MDRl gene and does not cross-react with endogenous mouse P-glycoproteins. 23 The majority of harvested cells expressed human P-glycoprotein at the time of transplantation, with 62% of the cell population being above background levels (Fig 2A) . Although there was some variation from one experiment to another (partly due to high nonspecific fluorescence levels of one isotype control antibody), the number of cells above background levels was reproducibly greater than 40% in six independent experiments. However, because the cell population appeared to be homogeneously shifted towards higher fluorescence, this percentage may underestimate the transduction frequency. The number of cells expressing P-glycoprotein did not change significantly when cells were cocultured for extended periods up to 16 days (data not shown). The expression levels, indicated by the ratios of peak channels as compared with the respective isotype controls, were comparable to that of colchicine-selected multidrug-resistant KB-8-5 cells ( Fig  2E) . Drug-sensitive parental KB-3-1 cells (Fig 2D) and highly multiply resistant KB-V1 cells (Fig 2F) served as negative and positive biologic specificity controls in these experiments. GP + E86 MDRl/A retrovirus-producing cells served as a positive control displaying much higher fluorescence intensity than the transduced hematopoietic cells ( Fig  2B) . In addition, the large retrovirus producing fibroblasts had higher forward and side scatter signals than the harvested hematopoietic cells (not shown). Logical gating for the combined forward and side scatter properties and for MRK16- creased reaction with antibody MRK16 was detected. However, the staining intensity of the isotype control (Pharmingen) was slightly higher than MRK16 in some experiments (Fig 2C) .
The drug transport function of P-glycoprotein in hematopoietic cells was shown by extrusion of a substrate, rhodamine-123. Cells harvested after 6 days in coculture with GP + E86 MDRUA producer fibroblasts displayed reduced rhodamine-l23 fluorescence that was specifically reversed by addition of a P-glycoprotein inhibitor, verapamil ( Fig  3A) . The efflux function of P-glycoprotein in transduced cells was comparable to that of KB-8-5 cells (Fig 3D) . KB-3-1 ( Fig 3C) and KB-V1 (Fig 3E) were negative and positive controls, respectively. No verapamil-reversible efflux was noted in cells transduced with GP + E86 + N2 virus producers that served as a negative control in these experiments (Fig 3B) .
From these experiments it could not be excluded that only maturing progenitors had been targeted by retroviruses, whereas those cells that retained the Lin-MHC II-Sca-l+ phenotype after 1 week in culture were not transduced. Because the majority of cells differentiated into myelomonocy- toid lineages during the culture period, a resorting experiment was performed to confirm that the primitive progenitor subpopulation also expressed human P-glycoprotein. After 7 days in coculture with retrovirus producing fibroblasts, floating cells were procured and purified using a MiniMACS separator. As described above, first cells expressing lineage or MHC class I1 antigens were removed, followed by positive sorting for Sca-l expression. As shown in Fig 4A, the resorted Lin-MHC 11-Sca-1 + cells were identified by MoAb MRK16, with 42% being above background levels (Fig 4A) . In comparison, the number of unfractionated MRK16-positive cells from the same coculture was 41% in this experiment (data not shown). Resorted Lin-MHC 11-Sca-1' cells actively effluxed rhodamine-l23 in a verapamil-reversible manner (Fig 4B) . Thus, primitive Lin-MHC II-Sca-lC cells were also transduced by retroviruses. In a control experiment using a neoR vector no false-positive staining of cells with antibody MRK16 was observed (data not shown).
Detection of the MDRl cDNA in peripheral blood of transplanted mice. Sublethally irradiated C57BL/6-SCIDSzJ mice were transplanted with various numbers of hematopoietic progenitor cells obtained from cocultures. Five to seven weeks after transplantation, the animals were tested by PCR for the presence of the human MDRl cDNA. The presence of MDRl cDNA was detected in l1 of 15 transplanted mice (Table 1 ). The intensities of the PCR signals varied between individual animals, even if they had been transplanted with identical numbers of pooled cells from the same cocultures. MDRI cDNA was also detectable in peripheral blood of three C57BL/6-SCID-SzJ mice that had undergone transplantation without previous irradiation. After more than 4 months, MDRl cDNA was detectable in all three mice; after 6 months it was detectable in one of two long-term surviving animals. We did not analyze long-term expression in animals that had undergone sublethal irradirrtion because these SClD mice were killed for the analysis of bone marrow. Taken together, MDRl cDNA was detectable in peripheral blood of 14 of 18 mice tested.
Expression of functional P-glycoprotein in bone marrow cells of recipient mice. Nine weeks after stem cell transplantation, four recipient C57BL/6-SCID-SzJ mice that had previously been tested by PCR were killed, and mononucleated bone marrow cells were analyzed by FACS. In two animals, the vast majority of cells displayed expression 
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Rhodamine-I23 fluorescence of human P-glycoprotein (Fig 5A, panels labeled M15 .4 and M16.1). The entire population of bone marrow cells appeared to be shifted towards higher fluorescence intensities using antibody MRK16 as compared with isotype controls (62.5% and 74.7% of cells above background levels for M15.4 and M16.1, respectively). As shown in Fig SB, Pglycoprotein was expressed in the majority of bone marrow cells both of the lymphocyte and the myelomonocytoid progenitor regions.
In one animal that was positive by PCR a bimodal distribution was observed with a minor population (approximately 25%) of cells stained positively with antibody MRK16, whereas one mouse that had no MDRI cDNA in peripheral blood displayed no P-glycoprotein in bone marrow (data not shown).
In a subsequent experiment, five sublethally irradiated CB.17-SCID mice received 2.5 X 10' donor cells transduced in coculture either with MDRl or neoR. Two recipient CB. 17-SCID mice displayed P-glycoprotein expression in the majority of bone marrow cells 8 weeks after transplantation (Fig 5A, panels labeled M17.1 and M17 .2). P-glycoprotein in bone marrow cells of these animals was functional as shown by rhodamine-l23 efflux experiments (Fig SC) . Negative controls for MRK16 and rhodamine efflux experiments included bone marrow cells of mice of donor and host strains and CB. 17-SCID mice that had been transplanted with cells LICHT ET AL transduced with neo' (Fig SA, panel N18 In conclusion, human P-glycoprotein was detectable in bone marrow cells of S of 7 mice analyzed. However, there was variation in the degree of expression among different mice. Verapamil-reversible rhodamine efflux was observed in bone marrow of mice transplanted with MDRI-transduced precursor cells, but not in controls.
Analysis of donor-derived and recipient populations in hone marrow qf CB. 17-SCID mice. Expression of P-glycoprotein in a very high percentage of the recipients' bone marrow cells strongly suggested that these cells were derived from donor mice. Because the C57BL/6-SCID-SzJ recipient mice were irradiated at nonmyeloablative doses and control mice survived without transplantation, experiments were performed to confirm the donor origin of bone marrow cells after transplantation. For these experiments, CB. 17-SCID mice that display the H-2K" phenotype were chosen as hosts for the transduced H-2Kh-positive donor cells. This procedure allows the identification of the donor-derived cell population with MoAbs to the respective H-2K antigens. Because they are not immunocompetent, SCID mice do not reject MHC-mismatched hematopoietic cells. Figure 6A shows that recipients M17.1 and M17.2 displayed a donor-type chimerism 8 weeks after transplantation. More than 90% of mononucleated bone marrow cells were derived from the H-2Kb-positive donor cells in these animals. These results are consistent with P-glycoprotein expression in the majority of bone marrow cells (Fig 5A) . One animal transplanted in parallel with cells from the same coculture, M 17.3, showed mixed chimerism. However, staining with MoAb MRK16 did not show significant P-glycoprotein expression in this mouse (data not shown). Of two mice reconstituted with neoK-transduced cells, N18.1 and N18.2, one showed mixed chimerism whereas engraftment of less than 10% was observed in the second one. Given the variation of PCR signals for MDRI cDNA among individual animals, the observed differences of engraftment between mice transplanted with either neoK-or MDRI-transduced cells are more likely due to individual variation of engraftment than to the retroviral vector used.
We next wished to determine whether the sorted and cultured donor cells had the capacity of multilineage engraftment. To this end, bone marrow cells of recipient mice were sorted with microbeads coated with MoAbs to the MHC class I antigen, H-2Kb, and analyzed for expression of lineage-specific antigens. Figure 6B shows results from animal M17.1. A major population of donor-derived cells expressed the myeloid differentiation antigen, Gr-I , whereas smaller proportions of cells were stained with antibodies B220 (CD4SR) to B and pre-B cells and to Thy-1.2, an antigen present on T cells and in low concentrations on stem cells. Thus, cells of multiple lineages in the host's bone marrow were derived from donor Lin-MHC 11-Sca-I cells.
Retransplantation of bone marrow. To prove Lin-MHC 11-Sca-1 + cells from cocultures had the capacity for repeated bone marrow engraftment, a retransplantation experiment 
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C57BL~6-scid was performed. Two C57BW-SCID-SzJ mice, M15.4 and M16.1, were transplanted with 2.5 X lo5 MDRI-transduced cells in two separate experiments as described above. They were tested by PCR and found to contain the human MDRl cDNA in peripheral blood. Nine weeks after transplantation these mice were killed and secondary recipient CB.17-SCID mice were reconstituted with 1 X lo6 unseparated nucleated bone marrow cells. Six weeks after the second transplantation the presence of human MDRl cDNA was analyzed by PCR. As shown in Fig 7, MDRl-transduced cells were detectable in 8 of 12 secondary recipient animals (4 of 6 secondary recipients transplanted with cells from each primary recipient mouse).
DISCUSSION
Our study shows that transfer of the human MDRI cDNA into a small population of marrow cells with stem cell prop-
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Rhodamine-l28 fluore8cenm R2 "xi erties is feasible. High expression of P-glycoprotein was achieved in these cells without the need for selection in vitro after exposure to retroviruses. After transplantation of transduced cells into SCID mice, P-glycoprotein was detectable in donor-derived cells in bone marrow. Expression levels and function of P-glycoprotein both in vitro and in vivo were comparable to those of colchicine-selected multidrugresistant -43-5 cells." KB-8-5 cells contain amounts of P-glycoprotein similar to most human multidrug-resistant neoplasms.24 However, we found considerable variability among mice even after transplantation with pooled cells from cocultures. Similarly, variations between individual mice after reconstitution with identical numbers of MDRl-transduced unseparated hematopoietic cells have been reported." In our study, this variability appeared in part to be due to differences of engraftment in recipient mice. Repopulation of bone marrow can result from one or from multiple clones.25 Moreover, gene-marking experiments have shown clonal The human MDRI cDNA was previously transduced into whole bone marrow cells with the use of retroviruses. Podda et al" detected the MDRI gene in peripheral blood of more than 90% of otherwise lethally irradiated mice after transplantation, and P-glycoprotein was observed in 14% of myeloid cells in these transplanted mice.I3 Sorrentino et al" reconstituted W/wv mice with MDRI-transduced bone marrow. Both studies indicate that MDRI-expressing cells were enriched after treatment with the MDR substrate taxol, which is a cytotoxic drug. Increased taxol-resistance of mice reconstituted with virus-transduced bone marrow was also described by Hanania and Deisseroth.'" In this study, the feasibility of serial transplantations with MDRI-transduced unseparated bone marrow cells was reported as proof that early hematopoietic precursor cells had been targeted. Very recently it was reported that the MDRI gene can be transferred into peripheral blood stem cells mobilized by treatment of spleenectomized mice with granulocyte colony-stimulating factor and stem cell factor." Fetal liver cells can be transduced by the use of ecotropic but not amphotropic retroviruses." Transfer of the MDRl gene into human CD34' bone marrow cells was shown by Ward et The transferred gene was detected by PCR in 18% to 70% of erythroid bursts and in 30% to 60% of myeloid precursors (colony-forming units-granulocyte-macrophage). P-glyco-1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 Fig 7. Detection of the MDRl gene in bone marrow of secondary recipient mice. Two C57BL/6-SCID mice were killed 9 weeks after bone marrow transplantation, and 1 x lo6 bone marrow cells were injected into sublethally irradiated CB.17-SCID mice. Six weeks after the second transplantation, bone marrow was procured, and DNA was prepared. MDRl cDNA was detected by PCR (35 cycles at 52°C for 2 minutes, 72°C for 2 minutes, and 94°C for 1 minutes) with primers specific for human MDRl and 0.5 p g of template DNA. Lanes 1 through 6, secondary recipients from animal M15.4; lanes 7 through 12, secondary recipients from animal M16.1; lane 13, normal C57BL/6 mouse (negative control).
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protein expression was found in 11.2% of progenitor cells in this study.
Earlier studies with mice transgenic for human MDRl cDNA driven by a chicken p-actin promoter had established that P-glycoprotein expression protects murine bone marrow cells from myelosuppression after chemotherapy with daunomycin or t a~o l . ' ' .~~ Initial evidence that a functional Pglycoprotein was capable of protecting hematopoietic precursor cells was provided by studies in which human bone marrow cells were transduced in vitro, and chemoresistance was shown using clonogenic assay^.^' Similarly, retroviral transduction of a human mutated dihydrofolate reductase (DHFR) cDNA into whole murine bone marrow protected progenitor cells from methotrexate toxicity. Mice transplanted with DHFX-transduced bone marrow displayed reduced sensitivity to meth~trexate.~' Presently, neither a unique surface antigen nor an in vitro assay specific for the most primitive, pluripotent stem cells is available. The human CD34+ population, for instance, consists of pluripotent stem cells and lineage-committed myeloid, erythroid, and lymphoid precursors. Similar heterogeneity has been reported for c-kir' cells, whereas Sca-l expression is believed to represent a more primitive population of progenitor cells.' Although the stem cell compartment in bone marrow is heterogeneous, several immunologic characteristics of murine hematopoietic cells with stem cell capacity have been described. It is well established that Lin-Scal + cells include most of the stem cells.* Based on comparable studies on HLA-DR expression in human cells, we have further restricted the population by depleting MHC class I1 antigens. Although there are several investigations on Lin-Sca-l+Thy-l" cells, the murine Lin-MHC 11-Sca-l+ population is less characterized. We found that MDRl-transduced Lin-MHC II-Sca-l+ cells were capable of competitive engraftment in bone marrow of sublethally irradiated mice, of sustained expression of the human MDRZ marker cDNA in bone marrow for more than 6 months, of multilineage engraftment, and of presence in bone marrow of secondary recipient mice after retransplantation. Taken together, these data support the conclusion that the sorted cell population has the characteristics of hematopoietic stem cells.
Cocultured Lin-MHC 11-Sca-1' donor cells populated multiple lineages in host mice, and expression of the transferred P-glycoprotein was observed both in the lymphocyte and the myelomonocytoid progenitor region. These observations are compatible with a pluripotent nature of Lin-MHC II-Sca-l+ cells. Alternatively, the purified cells may contain multiple progenitors that give rise to different clones of myeloid and lymphoid cells. The experiments performed do not prove that one single progenitor cell repopulated both myeloid and lymphoid cells and was thus truly pluripotent. This question could be addressed by fractionation of various differentiated cell populations in the recipients' bone marrow and Southern analysis of the retroviral integration sites. However, P-glycoprotein expression in lymphocytes does not result from transduction of differentiated donor lymphocytes because CD3+ and CD8a+ T cells and B220' B and pre-B cells were depleted during the sorting procedure. Lymphocytes were also undetectable in cocultures at the time of transplantation.
We have initially attempted to transplant stem cells transduced with the human MDRl cDNA into lethally irradiated C57BLJ6 mice. These animals showed P-glycoprotein expression in bone marrow. However, they were anemic and the majority died between days 15 and 30 in these experiments (data not shown). Delayed engraftment after transplantation of retrovirally transduced stem cells has been described.* Even without retroviral transduction, pluripotent stem cells may be incapable of rescuing lethally irradiated mice if they require several weeks to generate sufficient numbers of differentiated progeny.' To circumvent the problems caused by lethal irradiation, cotransplantation with a large excess of "compromised" marrow cells, generated by two cycles of bone marrow transplantation and engraftment, has been performed.' In our study SCID mice were used as hosts because in these animals donor bone marrow can be engrafted without lethal irradiation. Despite variations between individual recipient animals, our observations clearly show that in vitro-transduced Lin-MHC 11-Sca-l + cells have high engraftment capacity.
In this study, the cell population was purified with immunomagnetic particles contained Lin-MHC 11-Sca-1-cells whereas lineage antigen-expressing cells were almost completely depleted. Sca-l-cells may contain short-term Blineage progenitors but virtually no myelomonocytic precurs o r~.~~ We found that the sorted cells differentiated mainly into myeloid and monocytic lineages, whereas B cells were undetectable after culturing for 1 week. Thus, the culture conditions described appear to preferentially support the growth of Lin-MHC II-Sca-l+ cells.
The number of cells injected into recipient mice was relatively high in the majority of our experiments, with more than 25,000 cells displaying the primitive stem cell phenotype present at the time of transplantation. This was possible because of expansion of progenitor cells ex vivo. Previous reports had indicated that high numbers of transplanted stem cells may be required for stable expression. Spain and Mulligan34 found the presence of foreign DNA for more than 3 months after the injection of 4,000 to 5,000 purified Sca-1 'Lin-Thy-l-cells that had been retrovirally transduced.
Although reconstitution was possible with lower cell numbers, gene expression was subsequently lost in their study.
Interestingly, we found sustained presence of MDRl cDNA in peripheral blood of SCID mice that had not undergone irradiation. Although the number of animals in this preliminary experiment was low, this approach deserves further study. Recent investigations have questioned the need of creating "space" in bone marrow for donor stem cells by irradiation or ~hemotherapy.".'~ Gene transduction performed by coculture with virus-producing cells is more effective than addition of tissue culture Supernatant-containing virus.' In contrast to previous investigations, we cultured isolated hematopoietic cells for extended periods that was made possible by supplementation of media with a combination of growth factors at high concentrations. The rationale for this approach was to provide extended time periods for recruiting higher numbers of qui-escent stem cells by adequate stimulation. A recently reported combination for expansion of human peripheral blood progenitor cells by stem cell factor, erythropoietin, IL-1, IL-3, and IL-637 was found suitable for growth of Lin-MHC 11-Sca-1' cells. These and other factors have been found to act in a synergistic manner, whereas each growth factor alone is much less a~t i v e . "~~~* . '~ Recently, a combination of IL-3, IL-6, stem cell factor, and leukemia-inhibiting factor (LIF) has been shown to allow efficient transfer of a neoR marker gene into hematopoietic stem cells4 We omitted the use of late-acting factors that support the differentiation of stem cells into lineage-committed cells, eg, macrophage colonystimulating factor, granulocyte-macrophage colony-stimulating factor, or IL-5. In addition, the presence of virus-producing cells or NIH 3T3 cells in the cultures appeared to be beneficial for growth of hematopoietic cells. These fibroblasts presumably produce additional factors that support proliferation of hematopoietic cells. In our study, 12% to 15% of cells preserved the Lin-MHC II-Sca-l+ phenotype in culture until the time of transplantation. Longer periods of coculturing appear to be not advantageous because this proportion was decreased thereafter without further increase of P-glycoprotein expression (data not shown). We also showed that not only maturing progenitors but also the primitive Lin-MHC 11-Sca-l' cells were efficiently transduced in coculture and expressed the encoded protein.
The protocol described here permits the expression of a functional foreign protein in a high proportion of bone marrow cells after gene transfer into hematopoietic stem cells. High numbers of hematopoietic progenitor cells with sufficient engraftment capacity for bone marrow transplantation are generated in culture during gene transduction. If applicable to human hematopoietic stem cells, similar cell culture conditions may be helpful for clinical treatment of hematopoietic disorders. Because the purpose of this study was to show that high transduction frequencies can be achieved in vivo, the most efficient system, ie, cocultivation, was used. However, coculture with virus-producing fibroblasts cannot be used in human gene therapy. Further studies should address the applicability of this protocol to gene transduction systems that are based on repeated addition of virus containing culture supernatant to stem cells. Coculture with stroma cells may provide additional growth support if the presence of virus-producing fibroblasts is omitted.
Based on results of previous animal studies showing that P-glycoprotein protected bone marrow from chemotherapyinduced myelosuppression, clinical trials on transfer of the MDRl gene into bone marrow cells of patients suffering from advanced breast cancer and ovarian carcinomas are under consideration. Thereby, high-dose chemotherapy with reduced risk of life-threatening myelosuppression would be facilitated. Because bone marrow micrometastases are frequent in breast cancer, gene transfer into isolated pluripotent stem cells would reduce the risk of unwanted transduction of P-glycoprotein in contaminating tumor cells. Stem cells can be harvested from the bone marrow of patients or from peripheral blood after chemotherapy or treatment with growth factors.
Because transduction of P-glycoprotein into hematopoietic cells allows selection in vivo, it may be helpful for somatic gene therapy of hematopoietic disorders. For instance, Gaucher's disease is characterized by accumulation of a glucosylceramide in glucocerebrosidase-deficient hematopoietic cells. These patients suffer from skeletal lesions and severe hepatosplenomegaly. Recently, Aran et a14" described a transcriptional fusion between MDRl and the glucocerebrosidase gene. Increased expression of the latter gene was achieved by selection with cytotoxic substrates of Pglycoprotein. Efficient transduction of such fusion genes into hematopoietic stem cells might allow treatment of patients by elimination of nontransduced bone marrow cells that produce but fail to metabolize toxic compounds.
